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In Response
Dear Sir:
The Letter to the Editor by Monath1 regarding our study
of co-administration of yellow fever (YF) 17D vaccine with
human Ig2 raises interesting points. The study evaluated the
effect of Ig co-administration on YF 17D viremia and immune
responses, and in doing so collected evidence regarding a
hypothesis to potentially explain an increase in reported
YF 17D vaccine-related adverse events (AEs). Before 1996
in the pre-hepatitis A virus (HAV) vaccine era, YF-specific
antibodies in Ig given to travelers as HAV prophylaxis at the
time of their YF 17D vaccination may have incidentally acted
to reduce YF 17D viremia and consequent AEs.
The study objectives were to assess the effect of
co-administered Ig, relative to saline control, on the propor-
tions and magnitudes of YF 17D viremia, antibody response,
T cell activation, and plasma cytokines. Persons were admin-
istered available contemporary Ig mimicking its historical
administration in travel clinics for prevention of HAV: 1) intra-
muscular (IM) by 1.5-inch needle and syringe to the upper
outer quadrant of the buttock; and 2) during a clinic visit
when 17D vaccine was also administered. The study found
that co-administered Ig, relative to saline control, did not
modify 17D viremia, 17D-specific antibody response, T cell
activation, or plasma cytokine levels. Those results argued
against the underlying hypothesis. An alternate hypothesis
for the increase in 17D adverse events is enhanced awareness,
surveillance and reporting of YF 17D AEs as called for by
the Centers for Disease Control and Prevention.3 Further-
more, our study enrolled young healthy adults, whereas travel
clinics administer YF 17D vaccine to a wider variety of the
population, including older persons in whom the incidence of
YF 17D AEs is greater.4,5
We agree that there could have been antibody or viral
titer differences in historical Ig or YF 17D reagents, respec-
tively. The 2006–2007 YF Ig study necessarily used available
contemporary commercial Ig and 17D vaccine, and different
results could have been obtained for persons administered
Ig or vaccine that differed intrinsically, quantitatively, or
qualitatively. Methods used for production or quantitation
of Ig or vaccine may differ in different eras, or as Monath
points out, for Ig the pool of serum donors may have
changed. To address that concern, before the study, we
tested 30 lots of Ig acquired through the Food and Drug
Administration, for neutralizing antibody against YF by
50% plaque-reduction neutralization test (PRNT50). The
lots were from 1990–2003 and had concentrations of 5%
to 16.5%. In all 30 lots, neutralizing antibody titers ranged
from 1:160–1:2,560 (median = 1:640) and were sustained
over time (Edupuganti S, unpublished data) (Figure 1).
The figure not only indicates sufficiently high titers of pro-
tective antibody in all lots but also lot-to-lot variability in
measured titers. Similar results were observed when log10
neutralizing index (LNI) assays were used; median LNI
values across all lots over time were 2.91 (range = 1.61–4.13).
A PRNT titer ³ 20 or an LNI > 0.7 is protective against
infection against yellow fever.6
Although Ig from 1990 through 2003 contained high levels
of protective antibody to yellow fever virus, making our
original hypothesis plausible, Monath points out that anti-
body levels at that time may have been even higher than
the amount given to patients tested in our study, which
might explain our negative findings. In addition, in our
study, we reported that at day 7 after Ig and vaccine admin-
istration, there was no serum antibody detectable in PRNTs
(Figure 1).2 Detectable PRNT titer may not capture all
antibody-mediated anti-viral activity in the vaccinated person
because antibody that binds virus in vivo may also act through
a number of Fc-mediated non-neutralizing functions not
detected by PRNT, including antibody-dependent cell-
mediated cytotoxicity, complement activity, and antibody-
dependent cell-mediated virus inhibition.7–10
The dose of Ig in the study was that recommended by
the manufacturer for HAV prophylaxis (0.06 mL/kg). The Ig
was co-administered with YF 17D during a single clinic visit,
again presumably as would have occurred for most travelers.
Whereas IM injection in the deltoid is typically performed
with a 5/8–1-inch needle and syringe, the YF Ig study nurses
administered Ig in the gluteal muscle, presumably as it
occurred in most travel clinics before 1996, to the upper
outer buttocks quadrant into gluteal muscle with a longer
1.5-inch needle and syringe, consistent with published immu-
nization and nursing guidelines for normal and overweight
body mass indexes (BMIs).11,12 As stated in the Materials and
Methods,2 participants received 2–3 injections of Ig or saline
depending on their weight (maximum of 2 mL/injection).
Monath postulates that Ig could have been delivered sub-
cutaneously because of obesity. Effectiveness of IM injections
are determined by BMI, sex, and thickness of subcutaneous
fat at the injection site, among other factors. In the YF Ig study,
sex was well balanced in both groups because randomization
was stratified by sex and race. The mean BMI of our entire
study cohort was 25.3 kg/m2; in the saline versus Ig groups BMI
did not differ (25.5 kg/m2 and 25.1 kg/m2, respectively; P = 0.72).
Likewise, participants in the overweight (25–29.9 kg/m2) or
obese (³ 30 kg/m2) BMI categories were distributed equally
across Ig and saline groups with 18 (45%) of 40 in each group
in these categories. For Ig versus saline groups, 5 (12.5%)
versus 3 (7.5%) were obese. Thus, sex and BMI, factors that
may influence subcutaneous fat thickness and IM injection
success, were equal in the two study groups.
Figure 1. Neutralizing antibodies against yellow fever in lots of
immune globulin, 1990–2003.
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We do not believe Ig administration factors differed sig-
nificantly from historical methods or impacted the results
or conclusion. For »90% of our study participants who had
normal or overweight BMIs, the needle length we used
should have been adequate per guidelines. However, Ig with
higher 17D-specific antibody could have produced a different
result and conclusion. Our study as performed had a nega-
tive result that failed to provide support, and thereby
argues against the underlying hypothesis, as stated in the
abstract and final paragraph.2 We agree that this negative
result cannot disprove the hypothesis.
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